This study focuses on individuals with early-stage Triple Negative Breast Cancer who still have residual disease, which means some cancer cells remain in the body, after receiving initial treatment. The initial treatment involves neoadjuvant therapy, which is medicine given before surgery to shrink a tumor. The purpose of this study is to evaluate the benefit of adding pembrolizumab to standard follow-up treatments.
Participants in this study will receive different combinations of medications as part of their adjuvant therapy, which is treatment given after the main treatment to lower the risk of the cancer returning. Some individuals will receive pembrolizumab along with capecitabine or olaparib. Other participants may receive tegafur, gimeracil, and oteracil. These medications are administered either through an intravenous infusion, which is medicine delivered directly into a vein, or by taking pills at home.
The Netherlands 
